Skip to main content

Advertisement

SpringerLink
Log in

ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance)

  • ASO VISUAL ABSTRACT
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Funding

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA233178, UG1CA233180, UG1CA233253, UG1CA233337, and UG1CA233373. Also supported in part by funds from Glaxo Smith Kline (40601) and Genentech (40603) and by grants from The Breast Cancer Research Foundation (40601 and 40603). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. https://acknowledgments.alliancefound.org.

Author information

Author notes

  1. David W. Ollila and Mehra Golshan have been contributed equally as senior authors to this manuscript.

Authors and Affiliations

  1. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Dana Farber Cancer Institute, 450 Brookline Avenue, Suite 1220, Boston, MA, 02215, USA

    Anna Weiss MD

  2. Breast Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA, USA

    Anna Weiss MD & Ann H. Partridge MD, MPH

  3. Alliance Statistics and Data Center, Weill Cornell Medicine, New York, NY, USA

    Jordan Campbell & Karla V. Ballman PhD

  4. Women and Infants Hospital of Rhode Island and Warren Alpert Medical School of Brown University, Providence, RI, USA

    William M. Sikov MD

  5. Division of Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

    Lisa A. Carey MD, ScM

  6. Department of Surgery, Division of Surgical Oncology, Duke University, Durham, NC, USA

    E. Shelley Hwang MD, MPH

  7. Department of Radiation Oncology, Huntsman Cancer Institute, Salt Lake City, UT, USA

    Matthew M. Poppe MD

  8. Department of Surgery, Division of Surgical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

    David W. Ollila MD

  9. Department of Surgery, Division of Surgical Oncology, Yale Cancer Center, New Haven, CT, USA

    Mehra Golshan MD, MBA

Authors
  1. Anna Weiss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jordan Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karla V. Ballman PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William M. Sikov MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lisa A. Carey MD, ScM
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Shelley Hwang MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Matthew M. Poppe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ann H. Partridge MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David W. Ollila MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mehra Golshan MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Weiss MD.

Ethics declarations

W.M.S. discloses honoraria from Lilly Oncology, not pertaining to the topic of this manuscript. M.P.: investor in start-up biotech company, PEEL Therapeutics, Inc. No clinical or commercial products at this time. Stock ownership AstraZeneca (<$3000).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weiss, A., Campbell, J., Ballman, K.V. et al. ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). Ann Surg Oncol 28 (Suppl 3), 436–437 (2021). https://doi.org/10.1245/s10434-021-10005-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10005-1

Search

Navigation